IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors

PURPOSE: Somatic mutations in IDH1/2 occur in ~20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2(MUT) enzymes produce D-2-hydroxyglutarate (D2HG), which associates with increases in DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in so...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Molenaar, Remco J., Radivoyevitch, Tomas, Nagata, Yasunobu, Khurshed, Mohammed, Przychodzen, Bartolomiej, Makishima, Hideki, Xu, Mingjiang, Bleeker, Fonnet E., Wilmink, Johanna W., Carraway, Hetty E., Mukherjee, Sudipto, Sekeres, Mikkael A., van Noorden, Cornelis J.F., Maciejewski, Jaroslaw P.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884732/
https://ncbi.nlm.nih.gov/pubmed/29339439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2796
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker